ascopubs.org

Gene-expression-profiling plus integrated multidisciplinary approach to detect new-generation risk-adapted prognostic index in smoldering myeloma and multiple myeloma (GIMPI).

The impact of glucagon-like peptide-1 agonists on MGUS progression in patients with type 2 diabetes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation

By Karen Roman SkylineDx said the FDA granted Breakthrough Device Designation to Merlin CP-GEP, the company’s gene expression profile test for risk assessment and clinical decision-making in patients ...
Medindia

SkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care

First and only melanoma gene expression profiling test that is both: Designated as an FDA Breakthrough Device and included in the NCCN guidelines for T1b and T2a cutaneous ...

Intracellular mechanisms promote tumor survival during hypoxia

Northwestern Medicine scientists have, for the first time, described the underlying mechanisms that regulate how cells ...